SILVERARC CAPITAL MANAGEMENT, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001816307
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 68 positions · Total reported value $400.45M · Top-10 concentration 49.7% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 64.6% · 15 new · 20 cut · 18 exited
Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2024 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 68 equity positions with a combined reported value of $400.45M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 49.7% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were MRUS ($36.90M), NUVL ($35.33M), RNAM ($21.15M). By sector, the heaviest allocations are Health Care 55.4%, Industrials 0.7%. Versus the prior quarter, allocation shifted toward Other (+2.9pp) and away from Health Care (-1.5pp), Industrials (-1.5pp).
Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 63% of names.
The largest new positions opened in Q2 2024 were ALNY ($8.75M), SNDX ($7.60M), SRPT ($6.64M).
Of the 18 positions fully exited versus the prior quarter, the largest were ALPN ($7.89M), CRNX ($5.98M), BOLD ($4.45M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
Fully Exited (vs previous quarter)
- ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $7.89M
- CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $5.98M
- BOLD BOUNDLESS BIO INC · prev qtr: $4.45M
- SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $3.54M
- CYTK CYTOKINETICS INC · prev qtr: $3.51M
- APGE APOGEE THERAPEUTICS INC · prev qtr: $3.32M
- XENE XENON PHARMACEUTICALS INC · prev qtr: $2.85M
- DXCM DEXCOM INC · prev qtr: $2.77M
Insider Transactions (Form 4)
Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-116845 (status: Approved), registered 2019-06-21
- Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 3 private funds, of which 2 hedge funds
- Website: silverarccapital.com
Portfolio Structure
- 67 positions · $855.33M reported value (Q2 2026)
- Top 10 holdings = 47.1% of reported value
- Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
- Average position size: $12.77M
Sector Tilt
- Health Care 98.1%
- Financials 1.9%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
- 4 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
623.63K | $36.90M | 9.21% | Add | |
| 2 |
|
465.71K | $35.33M | 8.82% | Add | |
| 3 |
|
517.73K | $21.15M | 5.28% | Add | |
| 4 |
|
1.10M | $18.49M | 4.62% | Add | |
| 5 |
|
7.82M | $18.45M | 4.61% | Add | |
| 6 |
|
486.31K | $16.57M | 4.14% | Hold | |
| 7 |
|
625.09K | $14.66M | 3.66% | Add | |
| 8 |
|
374.91K | $13.88M | 3.46% | Add | |
| 9 |
|
192.34K | $13.17M | 3.29% | Add | |
| 10 |
|
3.61M | $10.54M | 2.63% | Hold | |
| 11 |
|
1.21M | $10.17M | 2.54% | Add | |
| 12 |
|
140.00K | $9.38M | 2.34% | Add | |
| 13 |
|
36.00K | $8.75M | 2.19% | New | |
| 14 |
|
1.60M | $7.95M | 1.99% | Add | |
| 15 |
|
172.49K | $7.81M | 1.95% | Add | |
| 16 |
|
1.08M | $7.61M | 1.90% | Reduce | |
| 17 |
|
370.00K | $7.60M | 1.90% | New | |
| 18 |
|
184.66K | $7.58M | 1.89% | Hold | |
| 19 |
|
42.00K | $6.64M | 1.66% | New | |
| 20 |
|
560.88K | $6.61M | 1.65% | Hold | |
| 21 |
|
282.25K | $6.12M | 1.53% | Add | |
| 22 |
|
455.80K | $6.03M | 1.50% | Add | |
| 23 |
|
546.86K | $5.92M | 1.48% | Add | |
| 24 |
|
1.77M | $5.59M | 1.40% | Add | |
| 25 |
|
500.00K | $5.11M | 1.28% | Hold | |
| 26 |
|
2.50M | $5.03M | 1.25% | Reduce | |
| 27 |
|
5.50M | $4.95M | 1.24% | Reduce | |
| 28 |
|
1.00M | $4.70M | 1.17% | Add | |
| 29 |
|
101.19K | $4.56M | 1.14% | New | |
| 30 |
|
19.36K | $4.49M | 1.12% | Hold | |
| 31 |
|
304.63K | $4.40M | 1.10% | Add | |
| 32 |
|
999.27K | $4.24M | 1.06% | Add | |
| 33 |
|
100.00K | $3.47M | 0.87% | New | |
| 34 |
|
122.85K | $3.32M | 0.83% | New | |
| 35 |
|
67.30K | $2.78M | 0.69% | Reduce | |
| 36 |
|
70.52K | $2.77M | 0.69% | Add | |
| 37 |
|
1.81M | $2.77M | 0.69% | New | |
| 38 |
|
79.19K | $2.71M | 0.68% | Hold | |
| 39 |
|
473.00K | $2.68M | 0.67% | Reduce | |
| 40 |
|
260.01K | $2.59M | 0.65% | Reduce | |
| 41 |
|
1.47M | $2.58M | 0.64% | Hold | |
| 42 |
|
1.50M | $2.52M | 0.63% | Add | |
| 43 |
|
844.24K | $2.52M | 0.63% | Hold | |
| 44 |
|
1.06M | $2.50M | 0.62% | Reduce | |
| 45 |
|
109.89K | $2.49M | 0.62% | Hold | |
| 46 |
|
263.84K | $2.49M | 0.62% | New | |
| 47 |
|
495.47K | $2.47M | 0.62% | Hold | |
| 48 |
|
398.44K | $2.47M | 0.62% | Hold | |
| 49 |
|
3.08M | $2.00M | 0.50% | Hold | |
| 50 |
|
141.52K | $1.91M | 0.48% | New | |
FAQ
What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2024-Q2?
In its 2024-Q2 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 68 equity positions worth $400.45M in aggregate; its largest disclosed positions were MRUS ($36.90M), NUVL ($35.33M), RNAM ($21.15M).
How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?
SILVERARC CAPITAL MANAGEMENT, LLC reported $400.45M of long equity holdings across 68 positions as of 2024-Q2. Top-10 holdings account for 49.7% of reported value.
What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.